Beijing Foyou Pharma(601089.SH): The drug registration certificate for Elamod Tablet has been obtained.

Beijing Foyou Pharma (601089.SH) announced that it has recently received the Drug Registration Certificate (Certificate No. 2026S00906) for the production of Elamod tablets (specification: 25mg) issued by the National Medical Products Administration. The Elamod tablet, developed by SIMCERE PHARMA, was first approved for domestic market in China in August 2011 by the National Medical Products Administration for the treatment of active rheumatoid arthritis. The company received the notification of acceptance for application on October 23, 2024, and has recently received approval from the National Medical Products Administration. According to national regulations, obtaining the Drug Registration Certificate is equivalent to passing the consistency evaluation process.